CONFIDENTIAL TREATMENT REQUESTED Portions of this exhibit indicated by “[***]” have been omitted, and such omitted portions have been filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect...Confidential Treatment • November 21st, 2013 • Akorn Inc • Pharmaceutical preparations • New York
THIS STOCK AND ASSET PURCHASE AND LICENSE AGREEMENT, is entered into as of November 15, 2013 (the “Effective Date”), by and among MERCK & CO, INC., a New Jersey corporation (“Merck & Co., Inc.”), MERCK SHARP & DOHME CORP., a New Jersey corporation (“MSD”, and together with Merck & Co., Inc., collectively, “Merck”), INSPIRE PHARMACEUTICALS, INC., a Delaware corporation (“Inspire”), and OAK PHARMACEUTICALS, INC., a Delaware corporation (“Buyer”).
